NCT03477110View on ClinicalTrials.gov

Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 4, 2018

Primary Completion Date

April 21, 2021

Study Completion Date

January 26, 2024

Conditions
Glioblastoma
Interventions
DRUG

Temozolomide

Given PO

RADIATION

Radiation Therapy

Undergo radiation therapy

DEVICE

NovoTTF-200A Device

Undergo tumor treatment fields therapy using NovoTTF-200A device

PROCEDURE

Tumor Treating Fields Therapy

Undergo tumor treatment fields therapy using NovoTTF-200A device

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors
collaborator

NovoCure Ltd.

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT03477110 - Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma | Biotech Hunter | Biotech Hunter